指南与共识药物不良反应与药物警戒治疗药物监测与药物基因组学特殊人群用药

非洲药物不良反应负担与药物基因组学临床指南背景分析

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.
指南 / 共识 · Clin Pharmacol Ther · 2026-04-03

本研究基于非洲47个国家近10年数据,利用国际药物基因组学指南推断药物-基因相互作用相关不良反应。结果显示非洲国家仅报告VigiBase数据库中1%的不良反应,主要涉及抗感染药如依非韦伦,相关基因包括CYP2B6、CYP2D6和CYP2C19。

要点

  • 非洲药物不良反应报告仅占VigiBase的1%,药物警戒体系薄弱
  • 抗感染药如依非韦伦是主要不良反应来源
  • CYP2B6、CYP2D6、CYP2C19基因变异与高不良反应 prevalence 相关

核心结论

  • 非洲国家仅报告VigiBase数据库中1%的不良反应,提示药物警戒项目薄弱
  • 推断与高不良反应 prevalence 相关的药物基因包括CYP2B6、CYP2D6和CYP2C19
  • 该基础分析可为非洲大陆药物基因组学干预的优先级设定提供依据

研究设计与样本

  • 研究分析了非洲大陆47个国家过去10年的数据,针对与药物基因组生物标志物相关的部分药物,在缺乏药物基因组检测的情况下,利用国际指南推导药物-基因相互作用相关不良反应的定义,以推断药物基因组变异对不良反应 prevalence 的影响

主要发现

  • 非洲国家仅报告VigiBase数据库中1%的不良反应
  • 不良反应主要由抗感染药如依非韦伦引起
  • 推断与高不良反应 prevalence 相关的药物基因有CYP2B6、CYP2D6和CYP2C19

临床怎么用

  • 在缺乏药物基因组检测的非洲地区,可借助国际指南推断药物基因组变异对不良反应的潜在影响
  • 应优先关注依非韦伦等抗感染药相关的不良反应及CYP2B6、CYP2D6、CYP2C19基因变异

局限性

  • 分析基于有限数据,非洲药物警戒报告率低可能影响结果可靠性
  • 在缺乏药物基因组检测的情况下使用国际指南推导定义,可能存在推断偏差

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the increased evidence of how these variants contribute to adverse drug reactions (ADRs) or ineffective treatments. Considering the vast genetic diversity in Africa, there are significant gaps in understanding how much of a negative effect this might be having across healthcare across the continent. We therefore sought to establish the extent of ADRs from a subset of medicines shown to be associated with pharmacogenetic biomarkers from the last 10 years across 47 countries on the African continent. In the absence of pharmacogenetic testing on the African continent, we used international guidelines to derive a subset of definitions associated with published drug-gene-interaction associated ADRs to infer the role of pharmacogenetic variation on the prevalence of ADRs. The data showed that African countries report only 1% of ADRs in the VigiBase database, indicative of weak pharmacovigilance programs on the continent. Our analysis revealed that ADRs were mainly caused by anti-infectives such as efavirenz. The inferred pharmacogenes associated with high prevalence of ADRs were CYP2B6, CYP2D6, and CYP2C19. Using limited data, this foundational analysis may serve as the basis for stakeholders to prioritize pharmacogenetic interventions across the African continent.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Scholefield J, Mazhindu TA, Nagy M, et al. The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines. Clin Pharmacol Ther. 2026. PMID: 41932844. doi:10.1002/cpt.70269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。